J Retin.
2024 May;9(1):52-61. 10.21561/jor.2024.9.1.52.
Anti-vascular Endothelial Growth Factor Monotherapy and Pneumatic Displacement for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy
- Affiliations
-
- 1Department of Ophthalmology, Kim’s Eye Hospital, Seoul, Korea
- KMID: 2556467
- DOI: http://doi.org/10.21561/jor.2024.9.1.52
Abstract
- Purpose
To compare visual outcomes over 6 months between intravitreal anti-vascular endothelial growth factor (VEGF) therapy with or without pneumatic displacement in patients who were diagnosed with submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV).
Methods
This retrospective observational study included 12 eyes that underwent pneumatic displacement followed by anti-VEGF therapy (combined treatment group) and 17 eyes that underwent anti-VEGF monotherapy (anti-VEGF monotherapy group) for submacular hemorrhage secondary to PCV and were followed for at least 6 months. The best-corrected visual acuity (BCVA) was measured at diagnosis and at 1, 3, and 6 months. The BCVA at 6 months and degree of BCVA improvement during the 6 months of follow-up were compared between the 2 groups.
Results
In the combined treatment group, the mean (± standard deviation) logarithm of minimal angle of resolution BCVA values at the defined periods were 1.40 ± 0.54, 1.08 ± 0.63, 0.83 ± 0.57, and 0.79 ± 0.64, respectively. In the anti-VEGF monotherapy group, the mean BCVAs were 1.48 ± 0.47, 1.31 ± 0.48, 1.13 ± 0.52, and 1.04 ± 0.67, respectively. BCVA was significantly improved in both the combined treatment group (p = 0.012) and the monotherapy group (p = 0.026). Neither the BCVA at 6 months nor the degree of improvement in the BCVA was different between the 2 treatment groups (p = 0.269 and p = 0.300, respectively).
Conclusions
No notable difference in efficacy was observed between intravitreal anti-VEGF therapy with or without pneumatic displacement in treating submacular hemorrhage secondary to PCV.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Peripapillary Choroidal Thickness Change of Polypoidal Choroidal Vasculopathy after Anti-vascular Endothelial Growth Factor
- Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps
- Two-year Outcome of Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy
- A Case of Polypoidal Choroidal Vasculopathy and Serous Retinal Detachment in a Bilateral Dome-shaped Macula
- Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor
